2554-75-8

Usage

Uses

Used in Medicinal Chemistry:
N,N-dimethyl-5-nitropyridin-2-amine is used as a pharmaceutical intermediate for the synthesis of various medicinal compounds. Its unique chemical structure allows it to serve as a key building block in the development of new drugs, contributing to the advancement of pharmaceutical research and drug discovery.
Used in Drug Synthesis:
In the pharmaceutical industry, N,N-dimethyl-5-nitropyridin-2-amine is used as a precursor in the synthesis of active pharmaceutical ingredients. Its presence in the molecular structure of certain drugs can enhance their therapeutic properties, making it a valuable component in the creation of novel medications.
Used in Research and Development:
N,N-dimethyl-5-nitropyridin-2-amine is utilized in research laboratories for the study of nitropyridine chemistry and its potential applications in medicine. It aids scientists in understanding the mechanisms of action and the biological effects of nitropyridine-based compounds, which can lead to the discovery of new therapeutic agents.
Used in Chemical Synthesis:
Beyond its applications in medicinal chemistry, N,N-dimethyl-5-nitropyridin-2-amine can also be used in the synthesis of other organic compounds. Its versatile chemical properties make it a useful reagent in various chemical reactions, contributing to the development of new materials and products in different industries.

InChI:InChI=1/C7H9N3O2/c1-9(2)7-4-3-6(5-8-7)10(11)12/h3-5H,1-2H3

Upstream product

• 5683-33-0 2-(Dimethylamino)pyridine 
• 4093-89-4 N-methyl-5-nitropyridin-2-amine 
• 74-88-4 methyl iodide 
• 68-12-2 N,N-dimethyl-formamide 
• 124-40-3 dimethyl amine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 1585-74-6 dimethylchloroamine 
• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 127-19-5 N,N-dimethyl acetamide 
• 4487-59-6 2-bromo-5-nitropyridine 

Downstream Products

• 5418-51-9 5-nitro-2-pyridone 
• 124-40-3 dimethyl amine 
• 4928-43-2 N₂,N₂-dimethylpyridine-2,5-diamine 
• 5418-51-9 5-nitro-2-hydroxypyridine 
• 113509-58-3 2-(methylamino)-5-nitropyridine N¹-oxide 
• 4548-45-2 2-chloro-5-nitropyridine 
• 26878-31-9 N²,N²-dimethyl-pyridine-2,5-diyldiamine; hydrochloride 
• 119151-81-4 N₂,N₂-dimethyl-2,5-pyridinediamine hydrochloride 
• 1435933-28-0 C₁₉H₂₅N₃O₂ 

Relevant academic research and scientific papers

COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS

The invention relates to a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same. The variables are described herein.

A Novel One-Pot Synthesis of N,N-Dimethylaminopyridines by Diazotization of Aminopyridines in Dimethylformamide in the Presence of Trifluoromethanesulfonic Acid

Abstract: Diazotization of aminopyridines in the presence of trifluoromethanesulfonic acid gives the corresponding pyridinyl trifluoromethanesulfonates instead of expected diazonium salts. Pyridinyl trifluoromethanesulfonates can be converted to N,N-dimethylaminopyridines on heating in dimethylformamide via replacement of the trifluoromethanesulfonyloxy group. The reaction is accelerated under microwave irradiation. A novel one-pot procedure has been proposed for the synthesis of 2- and 4-(dimethylamino)pyridines from commercially available aminopyridines. The procedure provides high yields of the target products, and it can be regarded as an alternative to the known methods of synthesis of N,N-dimethylpyridin-4-amine (DMAP) widely used as base catalyst in organic synthesis.

As tyrosine kinase inhibitors of the nitrogen-containing heteroaromatic ring derivatives

The present invention relates to compounds as represented by general formula (I) as tyrosine kinase inhibitors, preparation method thereof, pharmaceutical compositions containing the compounds, and uses thereof for preventing and/or treating instances of B-cell related leukemia, inflammatory diseases and autoimmune diseases, wherein A, ring B, L1, L2, R1, R2, R3, a, b, c, d, e, p and q are as defined in the specification.

Discovery of potent transient receptor potential vanilloid 1 antagonists: Design and synthesis of phenoxyacetamide derivatives

We aimed to discover a novel type of transient receptor potential vanilloid 1 (TRPV1) antagonist because such antagonists are possible drug candidates for treating various disorders. We modified the structure of hit compound 7 (human TRPV1 IC50 = 411 nM) and converted its pyrrolidino group to a (hydroxyethyl)methylamino group, which substantially improved inhibitory activity (15d; human TRPV1 IC50 = 33 nM). In addition, 15d ameliorated bladder overactivity in rats in vivo.

PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY

Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

A simple synthesis of aminopyridines: Use of amides as amine source

A transition metal/microwave irradiation (or base) free synthesis of aminopyridines has been accomplished via C-N bond forming reaction between chloropyridine and a variety of simple amides under refuxing conditions.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Organic compounds

The present invention relates to novel benzimidazole derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them, wherein the compounds have the formula (I): in which the substitutents are as defined in claim 1 and salts, solvates, hydrates and N-oxides thereof.

SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS

The invention pertains to heteroaromatic compounds of the formula I, as defined herein, that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.

ANTHRANILAMIDES

The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, and Het are as defined herein. Compounds of the present invention are useful as Aurora kinase inhibitors.